Subscribe To
ATOS / 3 Penny Stocks Set to Pass the $5 Mark Soon
ATOS News
By Proactive Investors
October 30, 2023
Atossa Therapeutics' (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ
Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing more_horizontal
By Proactive Investors
September 8, 2023
Atossa Therapeutics' upcoming breast cancer trial results expected to drive stock higher
Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight' rating and a $5 price target on more_horizontal
By Proactive Investors
August 23, 2023
Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral Endoxifen
Atossa Therapeutics Inc (NASDAQ:ATOS) is targeting three different stages of the breast cancer continuum with its proprietary oral form of Endoxifen, more_horizontal
By Proactive Investors
August 14, 2023
Atossa Therapeutics rides strong momentum in 2Q to clinical advancements and corporate expansion
Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled its second quarter financial results highlighted by a strong balance sheet to support the company in co more_horizontal
By Proactive Investors
July 20, 2023
Atossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in Canada
Atossa Therapeutics Inc (NASDAQ:ATOS) has received what's known as a no objection letter from Health Canada in response to its clinical trial applicat more_horizontal
By Proactive Investors
July 11, 2023
Maxim upbeat on Atossa Therapeutics after recent updates
Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enroll more_horizontal
By Proactive Investors
July 10, 2023
Atossa Therapeutics provides update on Phase 2 breast density trial enrollment
Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing Phase 2 Karisma-Endoxifen study of its oral fo more_horizontal
By InvestorPlace
July 6, 2023
3 Penny Stocks to Make Your ‘Get Rich' Dreams Come True
When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much. more_horizontal